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This systematic review focuses on the 30-day mortality associated with open surgery and fenestrated endografts
for short-necked (,15 mm) juxtarenal abdominal aortic aneurysms. A search for studies published in English
and indexed in the PubMed and Medline electronic databases from 2002 to 2012 was performed, using
‘‘juxtarenal abdominal aortic aneurysm’’ and ‘‘treatment’’ as the main keywords. Among the 110 potentially
relevant studies that were initially identified, eight were in accordance with the inclusion criteria in the
analysis. Similar outcomes for open and endovascular repair were observed for 30-day mortality. No differences
were observed regarding the secondary outcomes (duration of surgery, hospital stay, postoperative renal
dysfunction and late mortality), except that the late mortality rate was significantly higher for the patients
treated with open repair after a median follow-up of 24 months. Fenestrated endografting is a viable
alternative to conventional surgery in juxtarenal abdominal aortic aneurysms with a proximal neck ,15 mm.
KEYWORDS: Abdominal Aortic Aneurysm; Juxtarenal Aneurysm; Fenestrated Endograft; EVAR.
Belczak SQ, Lanziotti L, Botelho Y, Aun R, da Silva ES, Puech-Lea˜o P, et al. Open and endovascular repair of juxtarenal abdominal aortic
aneurysms: a systematic review. Clinics. 2014;69(9):641-646.
Received for publication on March 14, 2014; First review completed on April 10, 2014; Accepted for publication on April 10, 2014
E-mail: belczak@gmail.com
Tel.: 55 11 2661-6487
& INTRODUCTION
A juxtarenal aortic abdominal aneurysm (JRAAA) is an
infrarenal aortic aneurysm extending to the renal arteries
without involving them and its incidence has been
estimated as approximately 16% of infrarenal aortic aneur-
ysm (1). Open surgery (OS) is a well-established gold-
standard JRAAA treatment for low-surgical-risk patients
and the 30-day mortality is estimated as being approxi-
mately 3.6% (ranging from 0.0% to 8.6%) of the patients
(2,3). For patients with severe comorbidities and/or a high-
risk for OS, endovascular repair (EVAR) has been a better
indication, with the 30-day mortality estimated as 1.7%
(ranging from 0.8 to 4.1) of the patients (4,5). Both
procedures are associated with early and late complications
related to renal dysfunction (6).
An important concern regards the length of the proximal
neck between the renal artery and the aneurysm. EVAR
techniques should be used in cases of longer proximal necks
(.15 mm) (2,7), whereas shorter necks (,15 mm) have been
considered a contraindication for such endovascular
approaches (4).
Customized fenestrated endografts have allowed a
proximal sealing zone of the grafts and thus enabled an
increasing number of patients to be eligible for EVAR. Some
centers have used such technology even for short-necked
JRAAAs with promising results (8,9).
The lack of well-standardized and homogeneous studies
on the treatment of short-necked JRAAAs confers remark-
able limitations for effectively comparing OS and EVAR. We
conducted this systematic review to analyze the outcomes of
OS and EVAR specifically in patients with short-necked
JRAAAs, focusing primarily on the 30-day mortality rate.
The secondary outcomes included the duration of surgery,
hospital stay, postoperative renal dysfunction and late
mortality.
& MATERIALS AND METHODS
Original articles published in English from 2002 to 2012
were searched in the Cochrane, PubMed and Medline
electronic databases. The main keyword for this search was
‘‘juxtarenal aortic abdominal aneurysm’’. References were
selected when the title of the article clearly regarded the
‘‘treatment’’ of JRAAAs and all of the abstracts were read to
select only original articles regarding OS or EVAR, exclud-
ing case reports, reviews and original articles involving
series with less than 15 patients.
The inclusion criteria for this review included original
articles reporting series greater than 15 patients with
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non-ruptured JRAAAs treated with OS or EVAR and, in this
case, with proximal necks ,15 mm. Publications reporting
(a) replicate data, (b) infrarenal aneurysms or not referring
to the length of the neck, (c) combined results with other
anatomical locations of aneurysms (without clear references
to the specific results observed in JRAAAs), and (d)
outcomes incompatible with those defined for this review
were excluded. Reports without clear patient data were
excluded.
The outcome measures defined for this review included,
primarily, the 30-day mortality rate and the secondary
objectives referred to the duration of surgery (in minutes),
hospital stay (in days), postoperative renal complications
(represented by renal dysfunction) and late mortality rate
(considering the mean follow-up in months).
The statistical analysis was performed by comparing the
outcomes of OS with those of EVAR. The equality of the
medians was analyzed using the Mann-Whitney Test and
Fishers Exact Test was applied for comparing the frequen-
cies of higher or lower medians reported in the studies. The
frequencies of the outcomes were compared with the Chi-
square Test. The mean follow-ups reported in the papers
were correlated with 30-day mortality, postoperative (PO)
renal dysfunction and late mortality with the application of
the Spearman Correlation Coefficient. The p-values were
two-sided and the differences were significant with p#0.05.
& RESULTS
In the search using the ‘‘juxtarenal abdominal aortic
aneurysm’’ keyword in the specified electronic databases,
134 articles were found (PubMed: 90; Medline: 41;
Cochrane: 3). Thirteen articles were not published in
English remaining and 121 articles remained. In eleven
Figure 1 - PRISMA flow diagram for the meta-analysis of open and endovascular repair of JRAAA with proximal neck ,15 mm.
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articles, the titles referred to issues other than the JRAAA
treatment. A total of 110 articles were identified as
potentially relevant studies to be screened for retrieval after
reading their abstracts and 28 papers remained to be
entirely read. Five articles were included in the active
manual search. Eight articles did not report the length of the
proximal neck of the JRAAA; nine articles presented
combined results (including different abdominal aortic
aneurysm sites, ruptured and non-ruptured aneurysms
and infected and non-infected aneurysms) (Figure 1).
Rigorously considering the inclusion and exclusion
criteria, eight studies were eligible for this systematic
review (Table 1), involving a total of 776 patients (483 for
OS and 293 for EVAR). Four retrospective studies refer to
the OS and three refer to the endovascular treatment of
JRAAAs (one prospective study). One prospective study
reports OS and EVAR. The EVAR studies refer to the use of
fenestrated endografts. The outcomes as reported by the
authors are presented in Table 2.
The percentages of male patients (83% and 90% for OS
and EVAR, respectively) as well as their mean ages (72 and
71, respectively) were similar for both groups. The range in
the 30-day mortality and the follow-up was significantly
(p= 0.04) wider in the OS group (2.5%, ranging from 0.8% to
8.6% and 28 months, ranging from 6 to 56 months,
respectively) compared with that in the EVAR studies
(0.9%, ranging from 0.0% to 2.0% and 21 months, ranging
from 13 to 24 months, respectively).
The distribution of the studies according to the medians
calculated from the reported results showed the frequency
of higher medians in the OS studies for the 30-day and late
mortality (Figure 2), although such differences were not
significant.
Considering the distribution of the patients according to
the type of repair they experienced, no differences were
shown in the rates of the 30-day mortality and PO renal
dysfunction; however, late mortality rates were significantly
higher in the OS compared with the EVAR series (Figure 3).
A significant positive correlation between the mean
follow-up and late mortality was observed in the OS repair
(r = 0.99) group, whereas non-significant low correlations
were observed between the follow-up and PO renal
dysfunction for the types of JRAAA repair (r = 0.27 for OS
and r = 0.40 for EVAR) and late mortality for EVAR (r = 0.38)
(Table 3).
The technical success (defined as target vessel perfusion)
in the fenestrated endografting of JRAAAs ranged from
97.7% to 99.7%. Endoleaks were reported in 7/293 patients
(2.4%) for Type I, in 24/193 patients (12.4%) for Type II and
in 4/193 patients (2.1%) for Type 3. In one of the studies,
which involved a series of 100 patients, Type II and III
endoleak data were not available.
& DISCUSSION
In the years since EVAR was proposed as an alternative
treatment of aortic abdominal aneurysms, approximately
75% of patients have been amenable to such an approach
(16). Approximately 40%-60% of these patients are candi-
dates for infrarenal EVAR (17) and of these, 16% of the
patients have JRAAAs (1).
Indications for EVAR incorporating fenestrations and
branches typically include proximal necks of at least 15 mm
(2,4). In addition, renal or visceral target vessels ,4 mm in
diameter are relative contraindications because of the
increased risk for arterial complications (18). More recently,
a number of studies have shown that fenestrated grafts
represent a promising approach for short-necked JRAAAs
(8,9,14,15), including those with a neck ,4 mm (7).
The early advantages of this type of approach (lower 30-
day mortality and shorter length of hospital stay) do not
always avoid longer-term morbidity, reintervention and
postoperative mortality (6); many authors continue to
recommend OS for such cases (11,12,19).
Despite rates of technical success greater than 90%,
fenestrated endografting for short-necked JRAAAs involves
higher costs, longer time in the operating room and more
human resources for the pre-, intra- and postoperative
management of the patients compared with OS (18).
Many recent cohort and review studies have focused on
the endovascular treatment of JRAAAs; however, in most
cases, the length of the proximal neck is not mentioned
(5,20,22). Most likely, the reported results combine the
outcomes of JRAAAs with sufficient proximal necks with
those that are short-necked, which could explain the wide
variation in 30-day mortality, PO renal complications and
late mortality in the different publications.
In our systematic search for publications on OS and on
EVAR for JRAAAs (excluding other anatomic aneurysm
sites), we found eight papers amenable for analysis (four on
OS, three on EVAR and one on both).
Similar 30-day mortality rates were observed in the OS
and EVAR studies. There was a significantly wider range in
the 30-day mortality in the OS (0.8% to 8.6%) studies
compared with that in the EVAR (0.0% to 2.0%) studies. In
reports on EVAR for JRAAAs that did not mention the
length of the proximal necks, the range of the 30-day
Table 1 - Publications on the treatment of juxtarenal aortic abdominal aneurysms systematically selected for this review.
Type of repair References Study design N Age
Mean Range
Open surgery Ockert et al., 2007 (10) Retrospective 35 86% 68 NR
Knott et al., 2008 (11) Retrospective 126 78% 74 55-93
Speziale et al., 2010 (12) Retrospective 92 94% 72 53-85
Tsai et al., 2012 (13) Retrospective 199 71% 74 51-93
Donas et al., 2012 (9) Prospective 31 87% 71 NR
EVAR* O’Neill et al., 2006 (14) Prospective 119 82% 65 46-102
Scurr et al., 2008 (15) Retrospective 45 91% 73 53-85
Verhoeven et al., 2010 (8) Retrospective 100 87% 73 50-91
Donas et al., 2012 (9) Prospective 29 100.0% 74 NR
NR: Not reported.
CLINICS 2014;69(9):641-646 Treatment of juxtarenal aortic aneurysms
Belczak SQ et al.
643
Figure 2 - Distribution of the studies on OS and EVAR reporting higher medians than the median calculated for all nine studies on the
treatment of juxtarenal aortic abdominal aneurysms.
Figure 3 - Distribution of the patients treated with OS (in five studies) and EVAR (in four studies) according to 30-day mortality, PO
renal dysfunction and PO general mortality rates.
Table 2 - Outcomes reported in the studies on OS or EVAR of the juxtarenal aortic abdominal aneurysms.
Type of repair References Outcomes
Duration of
surgery Hospital stay
30-day
mortality
Mean
follow-up
Renal
dysfunction
Late
mortality
Open surgery Ockert et al., 2007 (10) 215 m 4 d 8.6% 28 m 17.1% 20.0%
Knott et al., 2008 (11) 319 m 17 d 0.8% 48 m 18.0% NR
Speziale et al., 2010 (12) 205 m NR 1.1% 6 m 10.9% 9.8%
Tsai et al., 2012 (13) NR 10 d 2.5% 56 m 8.5% 29.6%
Donas et al., 2012 (9) NR 7 d 6.4% 14 m 6.5% NR
EVAR O’Neill et al., 2006 (14) 227 m NR 0.8% 19 m 15.9% 12.6%
Scurr et al., 2008 (15) 350 m 6 d 2.0% 24 m 15.6% 11.0%
Verhoeven et al., 2010 (8) 180 m 4 d 1.0% 24 m 2.0% 22.0%
Donas et al., 2012 (9) 290 m 4 d 0.0% 13 m 0.0% NR
NR: Not reported.
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mortality rates is wider than that observed in this systematic
review, varying from 0.8% (22) to 4.1% (5) The combination
of the results observed for JRAAAs and infrarenal aneur-
ysms could explain such observations.
Regarding the secondary objectives, differences were not
evidenced between the groups. The mean duration of
the surgery was longer, whereas the mean hospital stay
was shorter in the EVAR than in the OS studies, which
was in agreement with information published elsewhere
(6,11,12,19); however, such differences were not significant.
The late mortality rate in a median follow-up of 24 months
was significantly higher (p= 0.04) in the OS studies (23%;
75/326) than in the EVAR studies (16.0%; 42/264).
These findings impose reflections on two main concerns
because inverse results were expected. First, the main
indication for endovascular repair of JRAAAs refers to the
high surgical risk for older patients presenting important
comorbidities and such indications appear to have been
respected in the studies systematically selected for this
review. Second, the expected higher postoperative mortality
in EVAR is the point most focused on by the authors who
support OS for JRAAAs (11,12,19). The selected studies are
more recent and it is possible to hypothesize that the
learning curve and experience with fenestrated endograft-
ing have improved.
A significant positive correlation was found between the
mean follow-up and late mortality in the OS studies and not
in the EVAR studies, which could indicate that late
mortality in EVAR studies could be higher with a longer
follow-up. This type of analysis should be emphasized in
further studies comparing this outcome for the two types of
JRAAA treatment.
Although our selection did not include the surgical
techniques for the open repair, Tsai et al. (13) reported
several cases with supraceliac clamping, which could have
affected the results of OS because it increases the risks of
cardiac stress and renal and/or visceral ischemia/reperfu-
sion.
Higher rates of endoleaks were reported in a study
published six years ago (14) that involved 119 patients,
whereas lower rates were reported in a very well designed
prospective study published in 2012 (9) that involved 29
patients. These observations appear to contribute to the
concept that better experience with endovascular techniques
for JRAAA repair could result in better outcomes.
A specific limitation of this study is that some information
have not been reported in some publications. The technical
variations reported in the OS and EVAR studies did not
allow us to explore their influence on the outcomes in a
deeper analysis. Most of the publications refer to retro-
spective studies because prospective randomized trials have
not been performed, resulting in the evidence being of low
quality. Because only relatively small series from single
centers have been reported, establishing a substantial cohort
would most likely take time. These limitations support the
need for more standardized prospective studies on OS and
EVAR for JRAAAs.
This study is the first attempt at a systematic review that
focuses on the EVAR outcomes for only short-necked
JRAAAs (excluding any other anatomic aneurysm site or
combined results) and compares them with outcomes of OS.
Even considering the limitations of this study, we could
conclude that the outcomes of fenestrated endografting of
JRAAAs are very similar to those observed in OS, ensuring
that EVAR is a very promising alternative. We suggest that
fenestrated endografts involve more expensive devices,
more delayed and longer procedures and more human
resources for postoperative patient management (18), which
are significant considerations to be carefully analyzed in
EVAR selection.
& AUTHOR CONTRIBUTIONS
Belczak SQ performed the data search and analysis and writing. Lanziotti
L and Botelho Y performed the data search and analysis. Aun R, da Silva
ES, Puech-Lea˜o P and De Luccia N conducted the review.
& REFERENCES
1. Sarac TP, Clair DG, Hertzer NR, Greenberg RK, Krajewski LP, O’Hara PJ,
et al. Contemporary results of juxtarenal aneurysm repair. J Vasc Surg.
2002;36(6):1104-11, http://dx.doi.org/10.1067/mva.2002.129638.
2. Nordon IM, Hinchliffe RJ, Holt PJ, Loftus IM, Thompson MM. Modern
treatment of juxtarenal abdominal aortic aneurysms with febestrated
endografting and open repair: a systematic review. Eur J Vasc Endovasc
Surg. 2009;38(1):35-41, http://dx.doi.org/10.1016/j.ejvs.2009.02.012.
3. Jongkind V, Yeung KK, Akkersdijk GJM, Heidsieck D, Reitsma JB,
Tangelder GJ, et al. Juxtarenal aortic aneurysm repair. J Vasc Surg.
2010;52(3):760-7, http://dx.doi.org/10.1016/j.jvs.2010.01.049.
4. Ontario Health Technology Advisory Committee. Fenestrated endovas-
cular grafts for the repair of juxtarenal aortic aneurysms: an evidence-
based analysis. Ontario Health Technology Assessment Series
2009;9(4):1-51.
5. The British Society for Endovascular Therapy and the Global
Collaborators on Advanced Sten-Graft Techniques for Aneurysm
Repair (GLOBALSTAR) Registry. Early results of fenestrated endovas-
cular repair of juxtarenal aortic aneurysms in United Kingdom.
Circulation 2012;125(22):2707-15.
6. United Kingdom EVAR Trial Investigators, Greenhalgh RM, Brown LC,
Powell JT, Thompson SG, Epstein D, Sculpher MJ. Endovacular versus
open repair of abdominal aortic aneurysm. N Engl J Med.
2010;362(20):1863-71.
7. Verhoeven EL, Prins TR, Tielliu IFJ, van den Dungen JJAM, Zeebregts CJ,
Huklebos RG, et al. Treatment of short-necked infrarrenal aortic
aneurysms with fenestrated stent-grafts: short term results. Eur J Vasc
Endovasc Surg. 2004;27(5):477-83, http://dx.doi.org/10.1016/j.ejvs.2003.
09.007.
8. Verhoeven EL, Vourliotakis G, Bos WTGJ, Tielliu IFJ, Zeebregts CJ, Prins
TR, et al. Fenestrated stent grafting for short-necked and juxtarenal
abdominal aortic aneurysm: an 8-year single-centre experience. Eur J Vasc
Endovasc Surg. 2010;39(5):529-36, http://dx.doi.org/10.1016/j.ejvs.2010.
01.004.
9. Donas KP, Eisenack M, Panuccio G, Austermann M, Osada M, Torsello
G. The role of open and endovascular treatment with fenestrated and
Table 3 - Analysis of the median data regarding the outcomes reported in studies on open surgery and endovascular
repair of short-necked juxtarenal aortic abdominal aneurysms.
Outcomes OS + EVAR studies OS studies EVAR studies p-values
Duration of the surgery in minutes 227 (180 – 350) 215 (205 – 319) 258 (180 – 350) p=0.514
Hospital stay in days 6 (4 – 17) 8.5 (4 – 17) 4 (4 – 6) p=0.114
30-day mortality rate 1.1% (0 – 20.0%) 2.5% (0.8% - 8.6%) 0.9% (0 – 20.0%) p=0.317
Follow-up in months 24 (6 – 56) 28 (6 – 56) 21 (13 – 24) p=0.119
PO renal dysfunction rate 11.0% (0 – 17.1%) 11.0% (6.5% – 17.1%) 9.0% (0 – 15.9%) p=0.476
Late mortality rate 16.3% (9.8% – 29.6%) 20.0% (9.8% – 29.6%) 12.6% (11.0% - 22.0%) p=0.450
CLINICS 2014;69(9):641-646 Treatment of juxtarenal aortic aneurysms
Belczak SQ et al.
645
chimney endografts for patients with juxtarenal aortic aneurysms. J Vasc
Surg. 2012;56(2):285-90, http://dx.doi.org/10.1016/j.jvs.2012.01.043.
10. Ockert S, Schumacher H, Bockler D, Malcherek K, Hansmann J,
Allenberg J. Comparative early and midterm results of open juxtarenal
and infrarenal aneurysm repair. Langenbecks Arch Surg. 2007;392
(6):725-30, http://dx.doi.org/10.1007/s00423-006-0141-6.
11. Knott AW, Kalra M, Duncan AA, Reed NR, Bower TC, Hoskin TL, et al.
Open repair of juxtarenal aortic aneurysms (JAA) remains a safe option
in the era of fenestrated endografts. J Vasc Surg. 2008;47(4):695-701,
http://dx.doi.org/10.1016/j.jvs.2007.12.007.
12. Speziale FG, Ruggiero M, Sbariga E, Marino M, Menna D. Factors
influencing outcome after open surgical repair of juxtarenal abdominal
aortic aneurysms. Vascular 2010;18(3):141-6.
13. Tsai S, Conrad MF, Patel VI, Kwolek CJ, La Muraglia GM, Brewster DC,
et al. Durability of open repair of juxtarenal abdominal aortic aneurysms.
J Vasc Surg. 2012;56(1):2-7, http://dx.doi.org/10.1016/j.jvs.2011.12.085.
14. O’Neill S, Greenberg RK, Haddad F, Resch T, Sereika J, Katz E. A
prospective analysis of fenestrated endovascular grafting: intermediate-
term outcomes. Eur J Vasc Endovasc. 2006;32(2):115-23, http://dx.doi.
org/10.1016/j.ejvs.2006.01.015.
15. Scurr JR, Brennan JA, Gilling-Smith GL, Harris PL, Vallabhaneni SR,
McWilliams RG. Fenestrated endovascular repair for juxtarenal aortic
aneurysm. Br J Surg 2008;95(3):326-32.
16. Keefer A, Hislop S, Singh MJ, Gillespie D, Illig KA. The influence of
aneurysm size on antomic suitability for endovascular repair. J Vasc
Surg. 2010;52(4):873-7, http://dx.doi.org/10.1016/j.jvs.2010.04.064.
17. Arko FR, Filis KA, Seidel SA, Gonzalez J, Lengle SJ,Webb R, et al.Howmany
patients with infrarenal aneurysms are candidates for endovascular repair?
The Northern California experience. J Endovasc Ther. 2004;11(1):33-40.
18. Moore R, Hinojosa CA, O’Neal S, Mastracci TM, Cina` CS. Fenestrated
endovascular grafts for juxtarenal aortic aneurysms: a step by step
technical approach. Catheter Cardiovasc Interv. 2007;69(4):554-71,
http://dx.doi.org/10.1002/ccd.21081.
19. Pearce JD, EdwardsMS, Stafford JM, Deonanan JK, Davis RP, CorrieriMA,
et al. Open repair of aortic aneurysms involving the renal vessels. AnnVasc
Surg. 2007;21(6):676-86, http://dx.doi.org/10.1016/j.avsg.2007.07.011.
20. Greenberg R, Eagleton M, Mastracci T. Branched endografts for thoracoab-
dominal aneurysms. J Thorac Cardiovasc Surg. 2010;140(6 suppl):S171-8.
21. Coscas R, Kobeiter H, Desgranges P, Becquemin JP. Technical aspects,
current indications, and results of chimney grafts for juxtarenal aortic
aneurysms. J Vasc Surg. 2011;53(6):1520-7, http://dx.doi.org/10.1016/j.
jvs.2011.01.067.
22. Tambyraja AL, Fishwick NG, Bown MJ, Nasim A, McCarthy MJ, Sayers
RD. Fenestrated aortic endografts for juxtarenal aortic aneurysm:
medium term outcomes. Eur J Vasc Endovasc Surg. 2011;42(1):54-8,
http://dx.doi.org/10.1016/j.ejvs.2011.03.033.
Treatment of juxtarenal aortic aneurysms
Belczak SQ et al.
CLINICS 2014;69(9):641-646
646
